These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17845681)

  • 21. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J; Punekar YS; Morris J; Chung-Faye G
    Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of infliximab in treatment on inflammatory bowel disease and factors affecting the therapeutic effect].
    Zhou Y; Chen Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1833-8. PubMed ID: 24369257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why innovation in inflammatory bowel disease drug development will impact your practice.
    Sandborn WJ
    Clin Gastroenterol Hepatol; 2011 Mar; 9(3):211-3. PubMed ID: 21338946
    [No Abstract]   [Full Text] [Related]  

  • 24. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
    Verma AM; Patel A; Subramanian S; Smith PJ
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):88-89. PubMed ID: 33444534
    [No Abstract]   [Full Text] [Related]  

  • 25. [New drug financing model causes concerns].
    Moum B
    Tidsskr Nor Laegeforen; 2006 Nov; 126(21):2830. PubMed ID: 17086229
    [No Abstract]   [Full Text] [Related]  

  • 26. Alpha 4 integrin blockade in inflammatory bowel disease.
    Ghosh S
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii70-2. PubMed ID: 14532154
    [No Abstract]   [Full Text] [Related]  

  • 27. [Managing inflammatory bowel disease in the biologics era: treating beyond symptoms is not sufficient].
    Peyrin-Biroulet L
    Rev Prat; 2014 Nov; 64(9):1207-9. PubMed ID: 25638855
    [No Abstract]   [Full Text] [Related]  

  • 28. Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?
    Little RD; Ward MG; Sparrow MP
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2430-2431. PubMed ID: 36155249
    [No Abstract]   [Full Text] [Related]  

  • 29. Evolutionary biologic therapy for inflammatory bowel disease.
    Hanauer SB
    Curr Gastroenterol Rep; 1999 Dec; 1(6):467-9. PubMed ID: 10980987
    [No Abstract]   [Full Text] [Related]  

  • 30. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].
    Lichtenstein GR; Sbreu MT; Cohen R; Tremaine W
    Rev Gastroenterol Mex; 2006; 71(3):351-401. PubMed ID: 17140062
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of chronic inflammatory bowel diseases].
    Lémann M
    Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease.
    Quispel R; van der Worp HB; Pruissen M; Schipper ME; Oldenburg B
    Gut; 2006 Jul; 55(7):1056. PubMed ID: 16766769
    [No Abstract]   [Full Text] [Related]  

  • 33. Medical therapy of inflammatory bowel disease.
    Lichtenstein GR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):xv-xvi. PubMed ID: 15177548
    [No Abstract]   [Full Text] [Related]  

  • 34. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.
    Devlin SM; Bressler B; Bernstein CN; Fedorak RN; Bitton A; Singh H; Feagan BG
    Can J Gastroenterol; 2013 Oct; 27(10):567-71. PubMed ID: 24106727
    [No Abstract]   [Full Text] [Related]  

  • 35. Reply to de Vries HE, Van Oijen MGH, de Jong DJ. Safety of infliximab in inflammatory bowel disease needs to be debated. Clin Gastroenterol Hepatol 2009;7:603-604.
    Caspersen S; Mortensen C; Riis L; Jess T; Bendtsen F
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1257. PubMed ID: 19778634
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety of infliximab in inflammatory bowel disease needs to be debated.
    de Vries HS; Van Oijen MG; de Jong DJ
    Clin Gastroenterol Hepatol; 2009 May; 7(5):603-4. PubMed ID: 19166980
    [No Abstract]   [Full Text] [Related]  

  • 37. Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators.
    van der Valk ME; van Oijen MG; Ammerlaan M; Siersema PD; Oldenburg B
    Gut; 2012 Feb; 61(2):324-5. PubMed ID: 21450695
    [No Abstract]   [Full Text] [Related]  

  • 38. Is keeping the colon the ultimate marker of success in ulcerative colitis?
    Nguyen GC; Prather CM
    Gastroenterology; 2009 Oct; 137(4):1204-6. PubMed ID: 19717125
    [No Abstract]   [Full Text] [Related]  

  • 39. Infliximab failure in cap polyposis.
    Maunoury V; Breisse M; Desreumaux P; Gambiez L; Colombel JF
    Gut; 2005 Feb; 54(2):313-4. PubMed ID: 15647206
    [No Abstract]   [Full Text] [Related]  

  • 40. New contributions to consensus on biosimilars.
    Argüelles-Arias F; Barreiro-de-Acosta M; Carballo F; Hinojosa J; Tejerina T
    Rev Esp Enferm Dig; 2014 Mar; 106(3):228-9. PubMed ID: 25007024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.